MedTrace Logo

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

NCT05517265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2026-05-01

No results posted yet for this study

Summary

The goal of CICERO is to investigate the clinical outcome with a particular focus on prospective data on safety using acalabrutinib (+/- obinutuzumab) in CLL patients receiving co-medication with DOACs (edoxaban, rivaroxaban, dabigatran, apixaban) irrespective of treatment line.

Conditions

Interventions

DRUG

Calquence

acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.

DRUG

Calquence

acalabrutinib according to Calquence® SmPC.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Klaus Fenchel, Prof. Dr. · Onkologische Praxisklinik Hämatologie/ Onkologie und Gerinnungsstörungen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-12
Primary Completion
2026-03-20
Completion
2026-03-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05517265 on ClinicalTrials.gov